Please login to the form below
neurodegeneration
This page shows the latest neurodegeneration news and features for those working in and with pharma, biotech and healthcare.
Merck acquires pre-clinical biotech Calporta for up to $576m
Expands into early-stage neurodegeneration research field. Merck has taken a stake in the neurodegeneration research field, following the acquisition of San-Diego, US-based Calporta. .
Latest news
-
New data backs GeNeuro’s MS drug after Servier exit
GeNeuro opted to continue dosing patients in the open-label follow-up, and now says temelimab provided continued relative improvements in neurodegeneration measured by magnetic resonance imaging (MRI), including a reduction
-
UniQure gets speedy US review for Huntington’s gene therapy
Huntington’s is an inherited disorder associated with neurodegeneration in the basal ganglia and cortex, leading to involuntary movements, dementia, and behavioural changes.
-
Lilly partners with AC Immune on tau drug for Alzheimer’s
Mark Mintun. Lilly is undeterred by those setbacks however, and Mark Mintun – the company’s vice president of neurodegeneration and pain research – said that the agreement with AC Immune “represents another
-
Theranexus takes Alzheimer’s drug combo into clinic
While the ultimate aim of AD therapy is to develop treatments that affect the underlying cause of the neurodegeneration that leads to dementia, dozens of failed trials – particularly for anti-amyloid
-
Morning brief: New biotech launched, Merck and Moderna expand collaboration and more
Preclinical data suggest this could lead to treatments for diseases including lysosomal storage disorders, liver and muscle diseases, inflammatory disorders and neurodegeneration.
More from news
Approximately 2 fully matching, plus 24 partially matching documents found.
Latest Intelligence
-
A roadmap to the successful treatment of Alzheimer’s disease
Two proteins – Tau and beta-amyloid – are recognised as major hallmarks of neurodegeneration: tangles and other abnormal forms of Tau protein accumulate inside the brain cells and spread between cells, while ... Secondly, it is well understood that
-
Brain power: fresh approaches to Alzheimer’s drug discovery
US biotech company Alector, which is pioneering work in immuno-neurology and novel therapeutic approaches to treating neurodegeneration, raised $176m in an initial public offering in early February. ... Alector has devoted the last five years to the
-
Deal Watch October 2018
Dicerna/. Lilly. GalXC RNAi technology platform for targets in Cardiometabolic disease, neurodegeneration and pain.
-
Key considerations for disease- modifying Parkinson’s disease trials
dopamine due to neurodegeneration.
-
Holding on to hope for Alzheimer’s advances
abnormalities including seizures, neurodegeneration, cognitive deficits and hypomyelination…it is completely unclear whether BACE could be targeted in a manner to affect amyloid processing in a therapeutic manner, without serious
More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.
Latest appointments
-
Lilly strengthens team with in-house promotions
Importantly, this team will help us maintain focus as we work to bring forward new medicines in diabetes, cancer, immunology, neurodegeneration and pain.”.
-
Asceneuron appoints chief medical officer
He joins the neurodegenerative diseases specialist from Novartis, where he had served a s vice president of its neuroscience development franchise and therapeutic head for neurodegeneration since 2011.
-
Nouscom appoints COO and board members
Prior to this, she was the global head of neurodegeneration at Novartis, and worked in the healthcare sector of McKinsey &Company in Chicago.
-
Polleo Pharma co-founders join Chronos Therapeutics
Dr Murray (pictured above) brings over 20 years of drug discovery and early development experience to the role, spread across a range of therapeutic areas including dermatology, inflammation, neurodegeneration, psychiatry.
-
Sanofi appoints Pfizer's Rita Balice-Gordon to lead neurobiology research
including neurodegeneration, neuroinflammation and central nervous system inherited diseases.
More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest from PMHub
-
Are we ready for an Alzheimer's disease modifying treatment
As it is easier to prevent neurodegeneration (neuron death) than to reverse it, neuroscientists are starting to look for early markers, through genetic tests or blood tests, in order to diagnose
-
Innovative approaches in the treatment of multiple sclerosis
The pathogenesis of MS consists of two key components: focal inflammatory demyelination, and neurodegeneration.
-
Innovative approaches in the treatment of multiple sclerosis
The pathogenesis of MS consists of two key components: focal inflammatory demyelination, and neurodegeneration.
More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- EMA clears BMS’ oral multiple sclerosis drug Zeposia
- GSK plans to produces one billion doses of vaccine adjuvant for COVID-19
- EMA clears BMS’ oral multiple sclerosis drug Zeposia
- Roche/Gilead tag team fights COVID-19 with Actemra/remdesivir
- Merck’s Keytruda hits the mark in triple negative breast cancer
- Finalists 2020 - Communiqué Awards
- ASCO: Momentum gathers behind next wave of CAR-T therapies
- Lilly starts world first trial of an antibody drug for COVID-19
- Pfizer’s Ibrance misses the mark in early breast cancer
- Rise of the patient influencer
- Working together against COVID-19
- Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
PMHub
Aptus Health
Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...
Latest intelligence
- Working together against COVID-19
- Analysing social media conversations to see what HCPs are saying online about the global pandemic...
- Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
- Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
- Are biobetters a market access opportunity?
- Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....
Quick links
Infographics
